Evaluation of the Reproducibility of the Measurement of the QSM Signal (Quantitative Susceptibility Mapping)

Multiple Sclerosis Clinical Trial

— ERESI  

Official title:

Evaluation of the Reproducibility of the Measurement of the QSM Signal (Quantitative Susceptibility Mapping)

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04465448
• Other study ID #: JSY_2020_25
• Status: Terminated
• Start date: December 17, 2020
• Est. completion date: June 16, 2022

Study information

• Verified date: December 2022
• Source: Fondation Ophtalmologique Adolphe de Rothschild
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Many central nervous system pathologies have an inflammatory component, often associated with an accumulation of disability and more severe tissue damage. In multiple sclerosis, the inflammatory process is in part characterized by the activation of microglia, an entity of the innate inflammatory system, as well as a breakdown of the blood-brain barrier. During inflammation, activated microglia may contain high levels of iron, characterizing its activated state.

Description:

Several MRI imaging tools are known to be highly sensitive to tissue iron content and have become the method of choice to study brain iron, including in a pathological context such as multiple sclerosis. Quantitative magnetic susceptibility mapping (QSM) is an emerging technique to access non-invasively the iron content in brain tissue. For some years this technique has been used in MS to characterize white matter lesions. Changes in the QSM value of the lesions have made it possible to describe lesions surrounded by an iron ring. Susceptibility MRI has also been proposed to highlight lesions according to their chronology. The study of reproducibility is of particular importance when using QSM in longitudinal studies or in therapeutic trials. A better understanding of intra- and inter-subject variation in QSM measurements may also allow a more accurate estimate of the number of subjects needed to detect changes in studies. In order to be widely applied to various pathologies, it is therefore necessary to evaluate its reproducibility by estimating the intra- and inter-subject variability for future dissemination in clinical and pharmaceutical studies. In this project, the invstigators propose to study the reproducibility of QSM acquisition.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 18
• Est. completion date: June 16, 2022
• Est. primary completion date: June 16, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Subject over 18 years old
• Consent to participate in the study
• Beneficiary of a social protection scheme
• Healthy volunteers: Consent to be informed if an unexpected anomaly is revealed by the imagery.
• Patients: With MS defined according to McDonald's revised criteria for spatial dissemination and temporal or clinical or radiological temporal dissemination and who should benefit from MRI in the imaging department

Exclusion Criteria:

• Absolute contraindication to 3T MRI
• Realization of an injected MRI (gadolinium) in the previous year
• Patient benefiting from a legal protection measure
• Pregnant or breastfeeding woman
• For healthy volunteers: History of neurological pathology or neurological pathology in progress

Related Conditions & MeSH terms

• Multiple Sclerosis
• White Matter Hyperintensity

Intervention

Other:
• MRI
Those included will perform an MRI without injection to obtain the QSM then they will exit the machine and reinstall themselves there to perform the second measurement. They will then change the MRI machine to perform a third measurement

Locations

Country	Name	City	State
France	Hhopital fondation adolphe de rothschild	Paris

Sponsors (1)

Lead Sponsor	Collaborator
Fondation Ophtalmologique Adolphe de Rothschild

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	QSM signal difference at two acquisition times in white matter, on an individual scale		baseline